Ensovibep, a SARS-CoV-2 antiviral designed ankyrin repeat protein, is safe and well tolerated in healthy volunteers: Results of a first-in-human, ascending single-dose Phase 1 study.
Stojcheva N, Gladman S, Soergel M, Zitt C, Drake R, Lockett T, Marchand C, Fustier P, Stavropoulou V, Fernandez E, Pettigiani NL, Watkins K, Puri A, Watson R, Legenne P, Stumpp MT, Boyce M.
Stojcheva N, et al. Among authors: boyce m.
Br J Clin Pharmacol. 2023 Jul;89(7):2295-2303. doi: 10.1111/bcp.15747. Epub 2023 May 8.
Br J Clin Pharmacol. 2023.
PMID: 37057679
Free article.
Clinical Trial.